Black Diamond Therapeutics Inc (BDTX) Stock Price, Quote & News

Company Profile

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also dev...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 252 0848

Website: www.blackdiamondtherapeutics.com

Address:

245 First Street, 18th Floor, Cambridge, United States

BossTrade Jul. 14 at 9:23 PM

$BDTX Time to go balls deep in this one Set up for ATH

0 · Reply

chole1 Jul. 14 at 8:06 PM

$BDTX not sure someone at the company is awake and taking up the momentum!! what are they waiting for?

0 · Reply

BossTrade Jul. 14 at 4:23 PM

$BDTX Not smaller than a couple bil

0 · Reply

MagicalMeme Jul. 14 at 1:41 PM

$BDTX time to break 2 and leave it behind this week

0 · Reply

waugusti Jul. 14 at 10:41 AM

$BDTX it is an ex20 and pacc asset with response rate in pacc 80%. The market for bdtx gets smaller and smaller.

0 · Reply

chole1 Jul. 14 at 6:11 AM

$BDTX AZ just pickung up the DIZAL EGFR Ex20 asset for USD 600mn upfront and 900mn milestones, plus royalties.... this should be a wake up call for others and get BDTX back in focus!

0 · Reply

Acho5280 Jul. 14 at 1:49 AM

$BDTX is one of the most interesting small-cap biotech setups right now. The market is still underestimating the potential of silevertinib. Phase 2 data showed strong activity in EGFR-mutated NSCLC, including a 60% ORR and encouraging durability. The question now isn't whether there is activity, it's whether Wall Street starts pricing in the commercial opportunity. Upcoming catalysts to watch: Q2 2026 update - pipeline progress, regulatory discussions, cash runway FDA pathway clarity - potential inflection point for the program Partnership/licensing potential - big pharma validation could change the valuation overnight

0 · Reply

RedPillBluePill Jul. 13 at 5:20 PM

$BDTX Since they got these algos playing pricing games, I’m about to play one of my own. It’s called “Discounted Afternoon Green fees, & $5 Par or better bets” Back at this madness tomorrow .GLTA !

0 · Reply

BossTrade Jul. 13 at 2:40 PM

$BDTX Let it play out. Organic chart action Massive inst investment Insider buying

0 · Reply

chole1 Jul. 13 at 11:15 AM

$BDTX we need BDTX to either 1) do an AGEN like deal for the lung trial, or 2) find a strategic partner to finance the lung trial, or 2) have the company taken over. The FDA interaction should be soon and will determine which option makes most sense and is of highest value

0 · Reply